Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Pacira BioSciences Community
NasdaqGS:PCRX Community
2
Narratives
written by author
0
Comments
on narratives written by author
15
Fair Values set
on narratives written by author
Create a narrative
Community Investing Ideas
Pacira BioSciences
Popular
Undervalued
Overvalued
Pacira BioSciences
AN
AnalystHighTarget
Consensus Narrative from 5 Analysts
Aging Global Population And Opioid Shift Will Expand Surgical Markets
Key Takeaways Accelerated payer adoption and strategic partnerships position Pacira for outsized revenue growth, margin expansion, and rapid scaling across expanding pain management markets. Solid intellectual property protection and a robust clinical pipeline ensure durable high-margin revenues, minimized competition, and sustained long-term earnings growth.
View narrative
US$44.00
FV
42.8% undervalued
intrinsic discount
11.89%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
Pacira BioSciences
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Policy Changes And Partnerships Will Expand Ambulatory Market Reach
Key Takeaways Increased adoption of non-opioid solutions and expanded outpatient procedure coverage are expected to drive sustained revenue growth for the company. Strategic partnerships, manufacturing efficiencies, and clinical pipeline progress support margin improvement and innovation-driven expansion into new markets.
View narrative
US$30.80
FV
18.2% undervalued
intrinsic discount
9.18%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
11
users have followed this narrative
3 days ago
author updated this narrative
Your Valuation for
PCRX
PCRX
Pacira BioSciences
Your Fair Value
US$
Current Price
US$25.18
63.5% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-127m
1b
2015
2018
2021
2024
2025
2027
2030
Revenue US$1.0b
Earnings US$151.1m
Advanced
Set Fair Value